Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Intellia Thera CS (NTLA)

$12.53 -0.31 (-2.41%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	1.80B
Revenue (ttm)	67.67M
Net Income (ttm)	-412.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-609.86%
Debt to Equity Ratio	0.00

Volume	1,893,884
Avg Vol	4,939,336
Day's Range	N/A - N/A
Shares Out	140.13M
Stochastic %K	74%
Beta	1.81
Analysts	Sell
Price Target	$23.47

Company Profile

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-20...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 285 6200

Website: www.intelliatx.com

Address:

40 Erie Street, Suite 130, Cambridge, United States

invest2bfree Aug. 24 at 2:39 PM

$NTLA

0 · Reply

Nitro111 Aug. 24 at 2:37 AM

$NTLA any catalysts before the end of year?

2 · Reply

betrump Aug. 22 at 12:53 PM

$NTLA link

1 · Reply

GorillaofWallStreet Aug. 22 at 10:37 AM

$NTLA Cathie Woods bought 115,499 more shares on Friday.

1 · Reply

Juankow Aug. 21 at 8:02 PM

$NTLA is cooking, next week will be much better 😉

0 · Reply

Juankow Aug. 21 at 7:49 PM

$NTLA

0 · Reply

Tl5000 Aug. 21 at 7:18 PM

$NTLA ntla market cap $1.7 Bil mrna is $50 Bil get the picture?

0 · Reply

Juankow Aug. 21 at 3:59 PM

$NTLA shorts are fuked, they won't hold $13 too much and short squeeze soon

1 · Reply

Merlintrader Aug. 21 at 3:45 PM

$SLS $BEAM $NTLA $ARCT

0 · Reply

tictocen5 Aug. 21 at 2:07 PM

$NTLA back to 100s.

4 · Reply

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-08-07T11:56:04.000Z - 17 days ago

Intellia Therapeutics upgraded to Outperform from In Line at Evercore ISI

2026-08-07T11:50:20.000Z - 17 days ago

Intellia Therapeutics upgraded to Outperform from In Line at Evercore ISI

Aug 6, 2026, 8:00 AM EDT - 18 days ago

Intellia Therapeutics Earnings Call Transcript: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 18 days ago

Intellia Therapeutics Earnings release: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 18 days ago

Intellia Therapeutics Quarterly report: Q2 2026

2026-08-06T11:40:45.000Z - 18 days ago

Intellia Therapeutics reports Q2 EPS (80c), consensus (78c)

Aug 6, 2026, 7:00 AM EDT - 18 days ago

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Jul 30, 2026, 8:00 AM EDT - 25 days ago

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates

2026-07-15T21:20:17.000Z - 5 weeks ago

Intellia Therapeutics downgraded to Underperform from Peer Perform at Wolfe Research

2026-07-10T12:06:00.000Z - 6 weeks ago

Intellia Therapeutics price target raised to $17 from $12 at Wedbush

ALNY AZN IONS

2026-06-17T16:06:29.000Z - 2 months ago

Intellia Therapeutics rises 12.9%

2026-06-17T14:07:55.000Z - 2 months ago

Intellia Therapeutics rises 10.7%

2026-06-14T20:35:58.000Z - 2 months ago

Intellia Therapeutics presents additional results from Phase 3 HAELO trial

Jun 13, 2026, 7:30 AM EDT - 2 months ago

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Jun 9, 2026, 9:00 AM EDT - 2 months ago

Intellia Therapeutics Transcript: AGM 2026

Jun 3, 2026, 4:55 PM EDT - 2 months ago

Intellia Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 1, 2026, 7:30 AM EDT - 3 months ago

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

May 20, 2026, 2:35 PM EDT - 3 months ago

Intellia Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

2026-05-13T10:34:18.000Z - 3 months ago

Intellia Therapeutics price target raised to $17 from $13 at Bernstein

2026-05-13T10:28:35.000Z - 3 months ago

Intellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright

May 12, 2026, 6:40 PM EDT - 3 months ago

Intellia Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

2026-05-12T16:07:18.000Z - 3 months ago

Intellia Therapeutics price target lowered to $19 from $20 at BofA

2026-05-12T11:12:55.000Z - 3 months ago

Intellia Therapeutics price target lowered to $49 from $58 at Canaccord

2026-05-11T17:26:11.000Z - 3 months ago

Intellia Therapeutics reports Q1 EPS (81c), consensus (90c)

May 11, 2026, 7:30 AM EDT - 3 months ago

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

May 11, 2026, 7:30 AM EDT - 3 months ago

Intellia Therapeutics Earnings release: Q1 2026

May 11, 2026, 7:30 AM EDT - 3 months ago

Intellia Therapeutics Quarterly report: Q1 2026

May 5, 2026, 7:30 AM EDT - 3 months ago

Intellia Therapeutics to Participate in Upcoming Investor Conferences

2026-05-02T00:11:02.000Z - 4 months ago

Cathie Wood’s ARK Investment buys 141K shares of Intellia Therapeutics today

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Intellia Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Intellia Therapeutics Proxy statement: Proxy filing

2026-04-30T03:26:02.000Z - 4 months ago

Cathie Wood’s ARK Investment buys 2.4M shares of Intellia Therapeutics today

2026-04-29T15:02:56.000Z - 4 months ago

Intellia Therapeutics 16.7M share Secondary priced at $10.75

Apr 29, 2026, 7:00 AM EDT - 4 months ago

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

Apr 27, 2026, 4:01 PM EDT - 4 months ago

Intellia Announces Proposed Public Offering of Common Stock

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Intellia Therapeutics Transcript: Study result

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Intellia Therapeutics Press release: Study result

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Intellia Therapeutics Slides: Study result

Apr 27, 2026, 7:06 AM EDT - 4 months ago

Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial

Apr 27, 2026, 7:01 AM EDT - 4 months ago

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial

Apr 27, 2026, 7:00 AM EDT - 4 months ago

Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema

Apr 27, 2026, 7:00 AM EDT - 4 months ago

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

Apr 24, 2026, 4:05 PM EDT - 4 months ago

Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

Mar 9, 2026, 8:40 AM EDT - 6 months ago

Intellia Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 1:10 PM EST - 6 months ago

Intellia Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 7:30 AM EST - 6 months ago

Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026

Mar 2, 2026, 7:40 AM EST - 6 months ago

US FDA lifts clinical hold on Intellia's heart disease gene therapy trial

Mar 2, 2026, 7:30 AM EST - 6 months ago

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM

Feb 26, 2026, 8:00 AM EST - 6 months ago

Intellia Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:00 AM EST - 6 months ago

Intellia Therapeutics Annual report: Q4 2025

Feb 26, 2026, 8:00 AM EST - 6 months ago

Intellia Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 7:30 AM EST - 6 months ago

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Feb 19, 2026, 7:30 AM EST - 6 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Jan 27, 2026, 8:13 AM EST - 7 months ago

US FDA lifts clinical hold on Intellia's nerve disease trail

Jan 14, 2026, 12:00 PM EST - 7 months ago

Intellia Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 7:00 AM EST - 8 months ago

Intellia Therapeutics Slides: Corporate presentation

Jan 7, 2026, 7:30 AM EST - 8 months ago

Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 10, 2025, 3:17 PM EST - 10 months ago

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Nov 8, 2025, 5:13 PM EST - 10 months ago

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Nov 6, 2025, 9:30 AM EST - 10 months ago

Intellia Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 9:30 AM EST - 10 months ago

Intellia Therapeutics Earnings release: Q3 2025

Oct 29, 2025, 5:11 PM EDT - 10 months ago

US FDA places clinical hold on Intellia's two gene-editing treatment trials

Oct 27, 2025, 8:30 AM EDT - 10 months ago

Intellia Therapeutics Transcript: Study Update

Oct 27, 2025, 8:30 AM EDT - 10 months ago

Intellia Therapeutics Press release: Study Update

Oct 27, 2025, 7:38 AM EDT - 10 months ago

Intellia pauses late-stage trials of gene-editing treatment after serious liver event

Oct 27, 2025, 7:30 AM EDT - 10 months ago

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

Sep 30, 2025, 7:00 AM EDT - 11 months ago

Intellia Therapeutics Slides: Company Presentation

Sep 25, 2025, 9:52 AM EDT - 11 months ago

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Sep 18, 2025, 7:30 AM EDT - 1 year ago

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Sep 1, 2025, 8:43 AM EDT - 1 year ago

Why big players are pouring millions in THIS biotech stock

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Earnings release: Q2 2025

Aug 1, 2025, 7:30 AM EDT - 1 year ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jul 31, 2025, 7:30 AM EDT - 1 year ago

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

Jun 15, 2025, 10:45 AM EDT - 1 year ago

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Jun 11, 2025, 9:00 AM EDT - 1 year ago

Intellia Therapeutics Transcript: AGM 2025

May 18, 2025, 7:25 AM EDT - 1 year ago

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

May 13, 2025, 7:20 PM EDT - 1 year ago

Intellia Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 8, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Earnings Call Transcript: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Earnings release: Q1 2025

May 7, 2025, 7:00 AM EDT - 1 year ago

Intellia Therapeutics Slides: Corporate Presentation

May 1, 2025, 7:30 AM EDT - 1 year ago

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 9:50 AM EDT - 1 year ago

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Apr 14, 2025, 10:58 AM EDT - 1 year ago

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

invest2bfree Aug. 24 at 2:39 PM

$NTLA

0 · Reply

Nitro111 Aug. 24 at 2:37 AM

$NTLA any catalysts before the end of year?

2 · Reply

betrump Aug. 22 at 12:53 PM

$NTLA link

1 · Reply

GorillaofWallStreet Aug. 22 at 10:37 AM

$NTLA Cathie Woods bought 115,499 more shares on Friday.

1 · Reply

Juankow Aug. 21 at 8:02 PM

$NTLA is cooking, next week will be much better 😉

0 · Reply

Juankow Aug. 21 at 7:49 PM

$NTLA

0 · Reply

Tl5000 Aug. 21 at 7:18 PM

$NTLA ntla market cap $1.7 Bil mrna is $50 Bil get the picture?

0 · Reply

Juankow Aug. 21 at 3:59 PM

$NTLA shorts are fuked, they won't hold $13 too much and short squeeze soon

1 · Reply

Merlintrader Aug. 21 at 3:45 PM

$SLS $BEAM $NTLA $ARCT

0 · Reply

tictocen5 Aug. 21 at 2:07 PM

$NTLA back to 100s.

4 · Reply

Victor3392 Aug. 21 at 2:05 PM

$NTLA

0 · Reply

Shirzo Aug. 21 at 10:29 AM

$MRNA check $NTLA

0 · Reply

Shirzo Aug. 21 at 10:25 AM

$NTLA

0 · Reply

Juankow Aug. 21 at 10:16 AM

$NTLA back to $13 today

0 · Reply

Victor3392 Aug. 21 at 9:57 AM

$NTLA

0 · Reply

Merlintrader Aug. 20 at 8:42 PM

$NTLA The Phase 3 HAELO trial of lonvo-z is complete and positive, and the rolling BLA opened on April 27, 2026, putting Intellia in the most advanced regulatory position of the in vivo editing group. Institutional ownership stands at 82.89% of the register. Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/intellia-therapeutics-ntla-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=moderna-20ago2026

0 · Reply

MoneyMacG Aug. 20 at 7:10 PM

$ABCL $RR $NTLA $MXL $VKTX good

0 · Reply

SignoreRossi Aug. 20 at 6:18 PM

$NTLA Biotech Rollercoaster volatility

0 · Reply

Shirzo Aug. 20 at 6:15 PM

$NTLA

0 · Reply

Victor3392 Aug. 20 at 5:52 PM

$NTLA This will close 2-3 percent down for the day !

0 · Reply

SternInvesting10 Aug. 20 at 5:27 PM

$CRSP $NTLA Back to normal. Down you go you used and abused hoes.

1 · Reply

Merlintrader Aug. 20 at 4:59 PM

Who Will Be the Next Moderna? $SLS , $BEAM, $NTLA , $ARCT and the Biotech Stocks That Could See the Next Major Re-Rating https://www.merlintrader.com/next-moderna-biotech-sls-beam-ntla/

0 · Reply

1.0.0